Notification of Shareholder

Sareum Holdings PLC
24 April 2008


For immediate release                                         24 April 2008





                              SAREUM HOLDINGS PLC

                          ("Sareum" or "the Company")



                      Notification of Shareholder Interest



Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery
business, is pleased to announce that it was informed on 23 April 2008 that Mr
Joseph Edward Craven has purchased 14,200,000 Sareum ordinary shares of 0.025p
as part of the placing announced on 14 April, 2008. Mr Craven now holds
38,000,000 Sareum ordinary shares representing 4.6 per cent of the Company's
total voting rights.



Commenting on the announcement, Sareum's Chief Executive Officer, Dr Tim
Mitchell, said: "We are very pleased that Mr Craven has chosen to increase his
shareholding in Sareum."



Mr Joseph Craven added: "I have been an investor in Sareum since 2005 and have
great confidence in the Company's management team and long term strategy.  I am
pleased to be increasing my holding in this business."



For further information:


Sareum Holdings plc                                           01223 497700

Tim Mitchell, Chief Executive Officer
Buchanan Communications                                       020 7466 5000

Tim Anderson, Mary-Jane Johnson
Grant Thornton Corporate Finance                              020 7383 5100

Philip Secrett, Colin Aaronson





About Sareum Holdings plc



Sareum Holdings plc is a structure-based drug discovery business headquartered
in Cambridge, UK. The Company was formed in August 2003 to discover new drugs
for the treatment of cancer.  Sareum's unique approach aims to halve the time it
takes to discover new drug candidates.



A structure-based approach to drug discovery relies on knowledge of the
three-dimensional structure of the proteins that cause disease.  Once the
structure is known, potential drugs are designed to 'lock-in' to the protein
with the aim of reversing or arresting a disease's progression.  Knowledge of
the structure of the potential drugs and how they 'lock-in' to their target
protein assists greatly in the development of high-quality drug candidates.
Determining structure is a complex task and requires leading-edge equipment and
experienced staff.  Sareum's approach to structure determination utilises its
proprietary protein expression platform in order to produce multiple recombinant
proteins that accelerate structure determination using x-ray crystallography.



Once the structure is determined, the Company's innovative fragment screening
platform is used to identify novel chemical templates designed to interact with
the target protein.  Sareum then uses its high-throughput medicinal chemistry
platform to rapidly optimise these molecules and develop the most promising into
potential drug candidates.



Sareum aims to successfully deliver drug candidates for licensing to larger
pharmaceutical companies at the pre-clinical or early clinical trials stage.
This is funded by provision of its specialist drug discovery capabilities to
partners in the pharmaceutical and biotechnology industries.



Sareum joined the AIM market of the London Stock Exchange in October 2004 and
trades under the symbol SAR.  For further information, please visit
www.sareum.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange